print this page

Clinical Trials: Children's Health


Children’s Arthritis & Rheumatology Research Network (CARRANet): Accelerating Toward an Evidence Based Culture in Pediatric Rheumatology (IRB# 167921)

(Children's Health)
  • Principal Investor
    Peter Blier, MD, PhD
  • Summary

    The CARRANet Research Registry was created to improve outcomes and quality of life for all children through clinical and translational research. The CARRANet Registry will create a database for rheumatic diseases of childhood including but not limited to: Systemic Lupus Erythematosus (SLE) Juvenile Idiopathic Arthritis/Juvenile Rheumatoid Arthritis (JIA) , Juvenile Dermatomyositis (JDM), Juvenile Primary Fibromyalgia Syndrome (JPFS), and Localized Scleroderma (LS).

  • More Information

    Eligibility: 

    Onset of rheumatic disease prior to age 16 for JIA and prior to age 18 for all other rheumatic diseases.  

  • Study Site Location
    Baystate Pediatric Rheumatology, 3300 Main St. Springfield MA
  • Contact
    Mary Gervasini, BA, CCRP
    413.794.4158
    Email

MEM-MD 91 An Open-label study of the safety and tolerability of Memantine in Pediatric patients(6-12 y.o.) with Autism, AspergersDisorder or Pervasive Deveopmental Disorder Not otherwise Specified. (IRB# 338277-11)

(Children's health, Mental health)
  • Principal Investor
    Bruce Waslick, MD
  • Summary

    The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).  

  • More Information

    Eligibility

    Must be between the ages of 6-12 and meet the criteria for diagnosis of autism, Asperger’s Disorder or Pervasive Developmental Disorder not otherwise specified.  

  • Study Site Location
    3300 Main Street, Springfield, MA
  • Contact
    Julie Kingsbury
    413.794.1136
    Email